Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-06-08, Stock:ABBV, The news for the past five days is as follows:
2021-06-01: nan
2021-06-02: NEWS1: Senate Finance Committee launches probe into AbbVie's tax practices.NEWS2: AbbVie's Rinvoq Shows Encouraging Long Term Safety, Efficacy In Rheumatoid Arthritis, Psoriatic Arthritis Patients.NEWS3: AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference.NEWS4: Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year.NEWS5: AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress.NEWS6: AbbVie Faces U.S. Senate Pressure Over Tax Payments.NEWS7: New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress.NEWS8: 15 Most Valuable Pharmaceutical Companies In The World.
2021-06-03: NEWS1: AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study.
2021-06-04: NEWS1: Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL).
2021-06-07: NEWS1: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS2: AbbVie's Ibrutinib/Venetoclax Combo Potentially Chemo-free, Fixed-Duration Treatment Option in Leukemia.NEWS3: CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL).NEWS4: Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis.

Answer: Decrease